AB1037 Adipokines in Patients with Newly Diagnosed Inflammatory Joint Diseases
Authors: A. Kononoff, L. Arstila, K. Vuolteenaho, H. Kautiainen, P. Elfving, E. Savolainen, H. Niinisalo, J. Rutanen, O. Marjoniemi, E. Moilanen, O. Kaipiainen-Seppänen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Body composition is altered in inflammatory diseases, for example in inflammatory joint diseases, with less muscle mass and more adipose tissue. Metabolic syndrome (MetS) is an increasing global health issue contributing to the cardiovascular disease risk. Low grade inflammation through adipocyte derived adipokines is seen in MetS. Studies have been conducted to evalute the contribution of adipokines to the inflammation of rheumatic diseases and inherent cardioascular risk in established disease. <h3>Objectives</h3> To analyse adipokine levels in relation to MetS in patients with newly diagnosed, untreated rheumatoid arthritis (RA), spondyloarthritis (SpA) and undifferentiated arthritis (UA). <h3>Methods</h3> Patients with inflammatory joint diseases participating in Northern Savo 2010 study were evaluated for the presence of components of MetS according to the definition by National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII). Adipokines adiponectin, adipsin, leptin and resistin were analysed from plasma samples by enzyme immunoassay. <h3>Results</h3> One hundred and seventy-six patients, 47 with RA, 58 with SpA and 71 with UA, were classified according to metabolic condition. When analysing the levels of adiponectin, adipsin, resistin and leptin in various arthritides with MetS present or absent significant differences in leptin in all diagnostic categories, in adipsin in SpA and in adiponectin in UA were recovered. Of the tested adipokines along with the fulfillment of 0-1 or 2-3 or 4-5 components of NCEP-ATP III adiponectin showed linear decrease in RA and in UA, p=0.037 and &lt;0.001, respectively. In SpA leptin showed linear increase with increasing number of components, p=0.014, and in UA adipsin, resistin and leptin showed a similar trend, p=0.020, 0.028 and &lt;0.001, respectively. <h3>Conclusions</h3> Levels of the tested adipokines differed in various arthritis categories along with the metabolic condition suggesting that the inflammatory disease also contributes to the adipokine profiles in patients with rheumatic diseases. <h3>References</h3> Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;10:772-783. Scotece M, Conde J, Gomez R, Lopez V, et al. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators of Inflammation 2012; Article ID 125458. doi:10.1155/2012/125458. Review Kontunen P, Vuolteenaho K, Nieminen R, Lehtimäki L et al. Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. Scand J Rheuamtol 2011;40:256-262 Conde J, Scotece M, Lopez V, Gomez R, et al. Adipokines: novel players in rheumatic diseases. Discov Med. 2013;81:73-83. Review <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3615